CCEL
Cryo-Cell International, Inc.
CCEL has slightly lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over CCEL overall, supported by stronger fundamentals and stronger modeled upside.
CCEL Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Stable | |
| Weak |
CCEL's revenue and cash flow are currently stable, but its profitability and balance sheet are under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
CCEL PE Valuation
CCEL has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 68x next year's earnings.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
CCEL Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Decline | |
| -- | |
| Limited | |
| -- |
Analysts expect CCEL to return to profit, with revenue declining.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
CCEL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.08 | — |
| Q3 2026 | -$0.22 | -$0.15 |
| Q2 2026 | -$0.29 | -$0.26 |
| Q1 2026 | -$0.32 | -3300% |
| Q4 2025 | -$0.30 | -700% |
| Q3 2025 | -$0.07 | +$0.99 |
| Q2 2025 | -$0.03 | +$1.08 |
| Q1 2025 | $0.01 | +$1.17 |
| Q4 2024 | $0.05 | +$1.19 |
CCEL is still losing money, but far less than before: $0.22 per share over the past year, against $1.16 at its worst in early 2024.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over CCEL on earnings quality, reporting a profit while its opponent remains loss making.
CCEL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $7.8M | 0% |
| Q2 2026 | $7.8M | -1.9% |
| Q1 2026 | $7.7M | -3.6% |
| Q4 2025 | $7.8M | -2.3% |
| Q3 2025 | $7.8M | -3% |
| Q2 2025 | $7.9M | -1.4% |
| Q1 2025 | $8M | +1.5% |
| Q4 2024 | $8M | +1.9% |
CCEL's revenue has held roughly level: $8M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 28% | +3.8 points |
| Q2 2026 | 15% | -3.4 points |
| Q1 2026 | 10% | -3.3 points |
| Q4 2025 | -51% | -49 points |
| Q3 2025 | 24% | +7.1 points |
| Q2 2025 | 19% | +1.5 points |
| Q1 2025 | 13% | +2.8 points |
| Q4 2024 | -1.5% | +204 points |
CCEL has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over CCEL on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
CCEL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1M | -58% |
| Q2 2026 | $1.8M | +181% |
| Q1 2026 | $584.8K | -34% |
| Q4 2025 | $1.2M | -44% |
| Q3 2025 | $2.5M | +11% |
| Q2 2025 | $644.6K | +2891% |
| Q1 2025 | $892K | +$1.7M |
| Q4 2024 | $2.1M | +32% |
CCEL still generates free cash flow, though less than at its 2020 peak: $5M over the past year.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over CCEL on cash flow, with more consistent year-over-year improvement.
CCEL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +9.7K shares |
| 1 year | -0.1% | -8.5K shares |
| 3 years | -3.3% | -277K shares |
| 5 years | -7.2% | -627K shares |
| Available history | -4.1% | -347K shares |
CCEL has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $80,883 |
| Q2 2025 | $88,619 |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | $16,400 |
| Q2 2024 | $1.2M |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
CCEL Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.5x | High |
| Q2 2026 | 10.3x | High |
| Q1 2026 | 7.7x | High |
| Q4 2025 | 6.0x | High |
| Q3 2025 | 1.6x | Healthy |
| Q2 2025 | 1.8x | Healthy |
| Q1 2025 | 1.8x | Healthy |
| Q4 2024 | 2.0x | Healthy |
CCEL's net debt is about 6.5 years of its operating earnings (EBITDA), up from 1.6 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over CCEL on leverage, with a lower net debt burden relative to earnings.
CCEL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 66.8 | Neutral |
| Stochastic | 88.0 | Overbought |
CCEL's weekly RSI is 67 (neutral) and its Stochastic is 88 (overbought).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
CCEL PE vs Healthcare Sector
| Metric | CCEL | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CCEL has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
CCEL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.62 | 17% above |
| 20 week MA | $4.16 | 30% above |
| 50 week MA | $3.75 | 44% above |
| 100 week MA | $4.69 | 15% above |
| 200 week MA | $5.37 | 0.6% above |
CCEL has climbed back above all five of its weekly moving averages, and it's now 0.6% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
CCEL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $7.22 | $7.50 | +3.9% |
| 2021 | $7.50 | $12.4 | +65% |
| 2022 | $12.4 | $4.30 | -65% |
| 2023 | $4.30 | $5.75 | +34% |
| 2024 | $5.75 | $7.72 | +34% |
| 2025 | $7.72 | $3.50 | -55% |
| 2026 YTD | $3.50 | $5.40 | +54% |
CCEL has finished higher in four of the last six years. It's up 54% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over CCEL on returns for 2026, with the stronger performance.